A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Rasagiline (Primary)
- Indications Alzheimer's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms R2
- 07 Mar 2017 Planned End Date changed from 1 May 2017 to 15 Feb 2019.
- 07 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 15 Feb 2018.
- 04 Aug 2016 Planned End Date changed from 1 Mar 2017 to 1 May 2017.